Alpha-1 MP

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alpha1-Antitrypsin Deficiency

Conditions

Alpha1-Antitrypsin Deficiency

Trial Timeline

Jul 29, 2016 → Mar 15, 2017

NCT ID

NCT02870309

About Alpha-1 MP

Alpha-1 MP is a phase 1/2 stage product being developed by Grifols for Alpha1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02870309. Target conditions include Alpha1-Antitrypsin Deficiency.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02870348	Phase 1/2	Completed	Jul 29, 2016	Feb 16, 2021	Alpha1-Antitrypsin Deficiency
NCT02870309	Phase 1/2	Completed	Jul 29, 2016	Mar 15, 2017	Alpha1-Antitrypsin Deficiency
NCT02796937	Phase 3	Recruiting	Jul 1, 2016	Feb 1, 2029	Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
NCT01983241	Phase 3	Active	Nov 1, 2013	Jan 1, 2027	Pulmonary Emphysema in Alpha-1 PI Deficiency

Competing Products

3 competing products in Alpha1-Antitrypsin Deficiency

See all competitors

Product	Company	Stage	Hype Score
VX-864 + Placebo	Vertex Pharmaceuticals	Phase 2	35
Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)	Grifols	Phase 1/2	29
Alpha-1 MP	Grifols	Phase 1/2	29